The Quest For Sterility Assurance: A New Approach To Isolator Decontamination
![AST-CURIS-thumbnail AST-CURIS-thumbnail](https://vertassets.blob.core.windows.net/image/fdef1c92/fdef1c92-b8fa-45cf-9af6-a0ac84dadc77/375_250-ast_curis_thumbnail.jpg)
How can you address the decontamination challenges associated with isolated fill-finish operations? Meeting the sterility and regulatory thresholds in pharmaceutical manufacturing is a critical process. Conventional decontamination methods, predominantly utilizing high concentrations of hydrogen peroxide, present challenges regarding efficacy, residue, and operational downtime. A new innovation being explored, involves the implementation of low-concentration Vapor Phase Hydrogen Peroxide (VPHP) with patented Pulse™ technology, ensuring superior sporicidal reduction and operational safety. Here we explore this forward-looking approach to sterile parenteral drug manufacturing and solutions being used to reduce decontamination cycle time while maintaining sterility assurance and meeting industry demands effectively.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.